The U.S. Food and Drug Administration has approved Takeda’s ORZEYFUL (oveporexton) for adults with narcolepsy type 1, giving patients access to what the company describes as the first and only medicine that treats the underlying cause of the condition. The approval also makes ORZEYFUL the first orexin-based therapy in this area.
Takeda said adults who received ORZEYFUL in clinical trials had significant and meaningful improvement across the full range of narcolepsy type 1 symptoms compared with people who took placebo. Based on those results, the drug is being positioned as a potentially important shift in how the condition is managed.
The decision is notable because the treatment is designed around orexin, a pathway that has long been central to research into narcolepsy type 1. As a first-in-class medicine, ORZEYFUL could open a new treatment approach beyond therapies that focus mainly on symptom control.
Safety information released with the approval notes that ORZEYFUL may cause or worsen urinary frequency and urgency. Takeda said those effects were seen in pooled phase 3 studies in patients with narcolepsy type 1, highlighting an adverse-event profile that doctors and patients will need to consider alongside the drug’s benefits.
